Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioAtla ( (BCAB) ) has issued an announcement.
On December 30, 2025, BioAtla, Inc. held a special meeting of stockholders to vote on several capital-related proposals, including approval to issue 20% or more of its outstanding common stock under existing financing agreements and to authorize a potential reverse stock split, as well as the ability to adjourn the meeting if more proxy votes were required. Stockholders approved the issuance of common stock in excess of the exchange cap and the adjournment proposal, but there were not enough votes to approve the reverse stock split, prompting the company to adjourn the meeting and reconvene it virtually on January 12, 2026, to continue soliciting proxies on that item from stockholders of record as of November 25, 2025.
The most recent analyst rating on (BCAB) stock is a Hold with a $0.78 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.
Spark’s Take on BCAB Stock
According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.
The score is held down primarily by weak financial performance—no TTM revenue, persistent large losses and cash burn, and a move to negative equity. The earnings call adds support from meaningful clinical/regulatory progress and potential partnering, but low cash and rising quarterly net loss temper that. Technicals are mixed-to-neutral, and valuation is unattractive due to ongoing losses and no dividend.
To see Spark’s full report on BCAB stock, click here.
More about BioAtla
Average Trading Volume: 1,508,486
Technical Sentiment Signal: Hold
Current Market Cap: $46.27M
Learn more about BCAB stock on TipRanks’ Stock Analysis page.